This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Myeloid/lymphoid or mixed-lineage leukemia 2 (MLL2); MLL3	<p>A genomic study suggests that agonizing the histone methyltransferases MLL2 or MLL3 could help treat medulloblastoma. In a genomic analysis of tumor tissue from children with medulloblastoma, 16% of patients had inactivating mutations in MLL2 or MLL3. Next steps include determining the specific function of those mutations in medulloblastomas.</p> <p>SciBX 4(3); doi:10.1038/scibx.2011.66 Published online Jan. 20, 2011</p>	Patent pending; available for licensing from The Johns Hopkins University Technology Transfer Office	<p>Parsons, D.W. <i>et al. Science</i>; published online Dec.16, 2010; doi:10.1126/science.1198056 Contact: Victor E. Velculescu, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: velculescu@jhmi.edu Contact: Kenneth W. Kinzler, same affiliation as above e-mail: kinzlk@jhmi.edu Contact: Bert Vogelstein, same affiliation as above e-mail: vogelbe@gmail.com</p>